138 related articles for article (PubMed ID: 38706206)
1. Association of hydroxyurea adherence with transcranial Doppler screenings in children with sickle cell disease.
Knight LMJ; Tanabe P; Blewer AL; Goodrich J; King AA; Reuter-Rice K; Crego N
Pediatr Blood Cancer; 2024 Jul; 71(7):e31017. PubMed ID: 38706206
[TBL] [Abstract][Full Text] [Related]
2. Transcranial Doppler screening in Nigerian children with sickle cell disease: A 10-year longitudinal study on the SPPIBA cohort.
Lagunju IA; Labaeka A; Ibeh JN; Orimadegun AE; Brown BJ; Sodeinde OO
Pediatr Blood Cancer; 2021 Apr; 68(4):e28906. PubMed ID: 33522690
[TBL] [Abstract][Full Text] [Related]
3. Changes in Transcranial Doppler Flow Velocities in Children with Sickle Cell Disease: The Impact of Hydroxyurea Therapy.
Adegoke SA; Macedo-Campos RS; Braga JAP; Figueiredo MS; Silva GS
J Stroke Cerebrovasc Dis; 2018 Feb; 27(2):425-431. PubMed ID: 29056404
[TBL] [Abstract][Full Text] [Related]
4. Annual stroke incidence in Nigerian children with sickle cell disease and elevated TCD velocities treated with hydroxyurea.
Lagunju I; Brown BJ; Oyinlade AO; Asinobi A; Ibeh J; Esione A; Sodeinde OO
Pediatr Blood Cancer; 2019 Mar; 66(3):e27252. PubMed ID: 29797633
[TBL] [Abstract][Full Text] [Related]
5. Transcranial Doppler Screening Among Children and Adolescents With Sickle Cell Anemia.
Reeves SL; Madden B; Freed GL; Dombkowski KJ
JAMA Pediatr; 2016 Jun; 170(6):550-6. PubMed ID: 27064406
[TBL] [Abstract][Full Text] [Related]
6. Adherence to transcranial Doppler screening guidelines among children with sickle cell disease.
Eckrich MJ; Wang WC; Yang E; Arbogast PG; Morrow A; Dudley JA; Ray WA; Cooper WO
Pediatr Blood Cancer; 2013 Feb; 60(2):270-4. PubMed ID: 22744996
[TBL] [Abstract][Full Text] [Related]
7. Sickle-Cell Disease Co-Management, Health Care Utilization, and Hydroxyurea Use.
Crego N; Douglas C; Bonnabeau E; Earls M; Eason K; Merwin E; Rains G; Tanabe P; Shah N
J Am Board Fam Med; 2020; 33(1):91-105. PubMed ID: 31907250
[TBL] [Abstract][Full Text] [Related]
8. Feasibility trial for primary stroke prevention in children with sickle cell anemia in Nigeria (SPIN trial).
Galadanci NA; Umar Abdullahi S; Vance LD; Musa Tabari A; Ali S; Belonwu R; Salihu A; Amal Galadanci A; Wudil Jibir B; Bello-Manga H; Neville K; Kirkham FJ; Shyr Y; Phillips S; Covert BV; Kassim AA; Jordan LC; Aliyu MH; DeBaun MR
Am J Hematol; 2017 Aug; 92(8):780-788. PubMed ID: 28439953
[TBL] [Abstract][Full Text] [Related]
9. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial.
Ware RE; Davis BR; Schultz WH; Brown RC; Aygun B; Sarnaik S; Odame I; Fuh B; George A; Owen W; Luchtman-Jones L; Rogers ZR; Hilliard L; Gauger C; Piccone C; Lee MT; Kwiatkowski JL; Jackson S; Miller ST; Roberts C; Heeney MM; Kalfa TA; Nelson S; Imran H; Nottage K; Alvarez O; Rhodes M; Thompson AA; Rothman JA; Helton KJ; Roberts D; Coleman J; Bonner MJ; Kutlar A; Patel N; Wood J; Piller L; Wei P; Luden J; Mortier NA; Stuber SE; Luban NLC; Cohen AR; Pressel S; Adams RJ
Lancet; 2016 Feb; 387(10019):661-670. PubMed ID: 26670617
[TBL] [Abstract][Full Text] [Related]
10. The clinical effectiveness and cost-effectiveness of primary stroke prevention in children with sickle cell disease: a systematic review and economic evaluation.
Cherry MG; Greenhalgh J; Osipenko L; Venkatachalam M; Boland A; Dundar Y; Marsh K; Dickson R; Rees DC
Health Technol Assess; 2012; 16(43):1-129. PubMed ID: 23140544
[TBL] [Abstract][Full Text] [Related]
11. The Impact of Sickle Cell Anemia and Mental Health Diagnoses on Healthcare Use and Preventive Care among Children Enrolled in Medicaid, 2005-2012.
Gondhi JP; Dombkowski KJ; Scott EL; Reeves SL
J Pediatr; 2020 Sep; 224():79-86.e2. PubMed ID: 32446724
[TBL] [Abstract][Full Text] [Related]
12. Interventions for preventing silent cerebral infarcts in people with sickle cell disease.
Estcourt LJ; Kimber C; Hopewell S; Trivella M; Doree C; Abboud MR
Cochrane Database Syst Rev; 2020 Apr; 4(4):CD012389. PubMed ID: 32250453
[TBL] [Abstract][Full Text] [Related]
13. Secondary benefit of maintaining normal transcranial Doppler velocities when using hydroxyurea for prevention of severe sickle cell anemia.
Ghafuri DL; Chaturvedi S; Rodeghier M; Stimpson SJ; McClain B; Byrd J; DeBaun MR
Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 28035747
[TBL] [Abstract][Full Text] [Related]
14. Approximately 40 000 children with sickle cell anemia require screening with TCD and treating with hydroxyurea for stroke prevention in three states in northern Nigeria.
Galadanci AA; Galadanci NA; Jibir BW; Abdullahi SU; Idris N; Gambo S; Ali Abubakar SA; Kabo NA; Bello-Manga H; Haliru L; Bashir I; Aliyu MH; Galadanci JA; DeBaun MR
Am J Hematol; 2019 Nov; 94(11):E305-E307. PubMed ID: 31423630
[No Abstract] [Full Text] [Related]
15. Hydroxyurea lowers transcranial Doppler flow velocities in children with sickle cell anaemia in a Nigerian cohort.
Lagunju I; Brown BJ; Sodeinde O
Pediatr Blood Cancer; 2015 Sep; 62(9):1587-91. PubMed ID: 25847050
[TBL] [Abstract][Full Text] [Related]
16. Interventions for preventing silent cerebral infarcts in people with sickle cell disease.
Estcourt LJ; Fortin PM; Hopewell S; Trivella M; Doree C; Abboud MR
Cochrane Database Syst Rev; 2017 May; 5(5):CD012389. PubMed ID: 28500860
[TBL] [Abstract][Full Text] [Related]
17. What drives transcranial Doppler velocity improvement in paediatric sickle cell anaemia: analysis from the Sickle Cell Clinical Research and Intervention Program (SCCRIP) longitudinal cohort study.
Estepp JH; Cong Z; Agodoa I; Kang G; Ding J; McCarville MB; Hankins JS; Wang WC
Br J Haematol; 2021 Jul; 194(2):463-468. PubMed ID: 34131902
[TBL] [Abstract][Full Text] [Related]
18. Hydroxycarbamide treatment reduces transcranial Doppler velocity in the absence of transfusion support in children with sickle cell anaemia, elevated transcranial Doppler velocity, and cerebral vasculopathy: the EXTEND trial.
Rankine-Mullings A; Reid M; Soares D; Taylor-Bryan C; Wisdom-Phipps M; Aldred K; Latham T; Schultz WH; Knight-Madden J; Badaloo A; Lane A; Adams RJ; Ware RE
Br J Haematol; 2021 Nov; 195(4):612-620. PubMed ID: 34291449
[TBL] [Abstract][Full Text] [Related]
19. The association between hydroxyurea adherence and opioid utilization among Texas Medicaid enrollees with sickle cell disease.
Kang HA; Barner JC
J Manag Care Spec Pharm; 2020 Nov; 26(11):1412-1422. PubMed ID: 33119448
[No Abstract] [Full Text] [Related]
20. Missed Opportunities for Transcranial Doppler Screening Among Children With Sickle Cell Disease.
Reeves SL; Fullerton HJ; Cohn LM; Dombkowski KJ; Boulton ML; Braun TM; Lisabeth LD
Clin Pediatr (Phila); 2016 Oct; 55(12):1093-9. PubMed ID: 26538586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
